Medications

Tirzepatide: How It Works, Dosage, Results & Side Effects

GLP-1 Companion · 10 min read

Tirzepatide is a first-in-class medication developed by Eli Lilly that simultaneously activates two incretin hormone receptors—GLP-1 and GIP. Sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for weight management), it has rapidly become one of the most significant pharmaceutical developments of the past decade, with clinical results that have exceeded expectations across every major trial.

The Dual Agonist Mechanism: GLP-1 + GIP

Traditional incretin-based therapies like semaglutide target only the GLP-1 receptor. Tirzepatide was engineered as a single molecule that activates both GLP-1 and GIP receptors. This dual mechanism is believed to produce synergistic effects on insulin secretion, appetite suppression, and metabolic health.

What GLP-1 Does

• Stimulates glucose-dependent insulin release from the pancreas
• Suppresses glucagon secretion, which lowers blood sugar
• Slows gastric emptying, promoting satiety after meals
• Acts on appetite centers in the brain to reduce hunger

What GIP Adds

• Enhances insulin secretion in a glucose-dependent manner
• May improve fat metabolism and adipose tissue function
• Could contribute to improved lipid profiles
• May help protect beta cells in the pancreas

Brand Names and Approved Indications

• Mounjaro: FDA-approved in May 2022 for type 2 diabetes in adults as an adjunct to diet and exercise.
• Zepbound: FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.
• Zepbound for Sleep Apnea: FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first medication ever approved for OSA. Based on the SURMOUNT-OSA trial, which showed 55–63% reduction in sleep apnea severity and disease resolution in up to 50% of participants.

Dosing Escalation Schedule

Tirzepatide is administered as a once-weekly subcutaneous injection. Both Mounjaro and Zepbound use the same escalation schedule. The gradual approach is critical for minimizing gastrointestinal side effects.

1. 2.5 mg weekly for 4 weeks (starting dose for tolerability only)
2. 5 mg weekly for 4 weeks (first therapeutic dose)
3. 7.5 mg weekly for 4 weeks (if clinically appropriate)
4. 10 mg weekly for 4 weeks
5. 12.5 mg weekly for 4 weeks
6. 15 mg weekly (maximum dose)

Your healthcare provider may pause escalation at any dose where you are achieving adequate results and tolerating the medication well. Not everyone needs to reach 15 mg.

Clinical Trial Data: SURPASS Program (Diabetes)

The SURPASS trials evaluated tirzepatide in adults with type 2 diabetes across multiple comparators.

• SURPASS-1 (vs. placebo): HbA1c dropped by up to 2.07%; weight loss of up to 9.5 kg (21 lbs) at 40 weeks.
• SURPASS-2 (vs. semaglutide 1 mg): Tirzepatide was statistically superior in both HbA1c reduction (−2.46% vs −1.86%) and weight loss (−12.4 kg vs −6.2 kg) at 40 weeks.
• SURPASS-3 (vs. insulin degludec): Superior glycemic control with weight loss instead of weight gain.
• SURPASS-4 (vs. insulin glargine): Sustained HbA1c reduction with cardiovascular safety confirmed.
• SURPASS-5 (add-on to insulin glargine): Significant improvement in glycemic control even in patients already on basal insulin.

Clinical Trial Data: SURMOUNT Program (Obesity)

• SURMOUNT-1: Average weight loss of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) over 72 weeks in adults without diabetes. Over 57% of participants on 15 mg lost ≥20% of body weight; 36% lost more than 25%.
• SURMOUNT-2: Average weight loss of 14.7% at 15 mg in adults with type 2 diabetes and obesity.
• SURMOUNT-3: Combined with intensive lifestyle intervention, weight loss reached up to 26.6%.
• SURMOUNT-4: Continued treatment maintained weight loss; switching to placebo resulted in approximately 14% weight regain versus 1.5% additional loss for those who continued treatment.
• SURMOUNT-5 (published NEJM, 2025): First head-to-head RCT against semaglutide 2.4 mg. Tirzepatide achieved −20.2% versus −13.7% weight loss at 72 weeks. GI-related discontinuations were actually lower with tirzepatide (2.7% vs 5.6%).
• SURMOUNT-OSA: Tirzepatide reduced sleep apnea severity (AHI) by 55–63% in adults with obesity, leading to the December 2024 FDA approval for OSA.

SURPASS-2 was a pivotal head-to-head trial showing that tirzepatide outperformed semaglutide 1 mg in both glycemic control and weight loss. SURMOUNT-5 later confirmed this advantage in a head-to-head obesity trial comparing the maximum doses of both drugs—establishing tirzepatide as the more effective option when weight loss is the primary goal.

Side Effects Profile

Tirzepatide's side effects are broadly similar to other incretin-based therapies, with gastrointestinal symptoms being the most common.

• Nausea (reported in 12–24% of participants across trials)
• Diarrhea (reported in 12–17%)
• Vomiting (5–9%)
• Constipation (5–7%)
• Decreased appetite
• Abdominal pain
• Dyspepsia (indigestion)
• Injection site reactions

Serious adverse events are uncommon but include pancreatitis, gallbladder disease, and severe allergic reactions. Tirzepatide carries the same boxed warning as other GLP-1 agonists regarding thyroid C-cell tumors observed in animal studies.

Future Pipeline and Research

Eli Lilly and other pharmaceutical companies are exploring next-generation incretin therapies inspired by tirzepatide's dual-agonist success. Key areas of ongoing research include:

• Oral tirzepatide: Eli Lilly is developing an oral formulation currently in late-stage trials, which could eliminate the need for injections entirely.
• Retatrutide (triple agonist GLP-1/GIP/glucagon): Phase 3 TRIUMPH-4 results (December 2025) showed 28.7% weight loss at 68 weeks — the highest ever recorded in a Phase 3 obesity trial. Also reduced knee osteoarthritis pain by 75.8%. NDA filing expected Q4 2026.
• Tirzepatide for MASH/NASH: The SYNERGY-NASH trial showed 73.3% resolution of MASH at the highest tirzepatide dose versus 13.2% placebo — among the most striking data ever seen for a liver disease treatment.
• Tirzepatide for heart failure: Trials in heart failure with preserved ejection fraction (HFpEF) are ongoing, building on tirzepatide's established metabolic and cardiovascular benefits.
• Long-term cardiovascular outcomes: The SURPASS-CVOT trial will provide dedicated cardiovascular outcome data for tirzepatide in patients with T2D, complementing the existing SURPASS trial safety data.

The Bottom Line

Tirzepatide has set a new standard in the treatment of type 2 diabetes and obesity. Its unique dual GLP-1/GIP mechanism, strong clinical trial data, and favorable safety profile make it one of the most impactful medications of this generation. Whether prescribed as Mounjaro or Zepbound, tirzepatide offers patients a powerful tool—especially when combined with healthy lifestyle changes. Consult your healthcare provider to determine whether tirzepatide is appropriate for your situation.

Sources

• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.
• Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.